OVIDE
LOE Approachingmalathion
NDATOPICALLOTION
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
OVIDE (malathion) is cholinesterase inhibitors [moa]. Approved for lice infestations. First approved in 1982.
Drug data last refreshed 23h ago
Mechanism of Action
Cholinesterase Inhibitors
Indications (1)
Clinical Trials (20)
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
HR+ Advanced or Metastatic Breast Cancer
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
Human Immunodeficiency Virus (HIV)
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
Narcolepsy Without CataplexyNarcolepsy With Cataplexy
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.